Bioanalytical Services
 |
PharmaNet offers bioanalytical laboratory services through its subsidiaries: Anapharm, Anapharm Europe, Keystone Analytical and Taylor Technology.
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
 |
 |
 |
 |
 |
| Cabergoline | Central Nervous System Agents | LC/MS/MS | 1-50 pg/mL | Human EDTA Plasma |
| Cabergoline | Central Nervous System Agents | LC/MS/MS | 50-15000 pg/mL | Rabbit EDTA Plasma |
| Calcitriol | Rheumatology | LC/MS/MS | 5-500 pg/mL | Human EDTA Plasma |
| Candesartan | Cardiovascular | LC/MS/MS | 0.5-250 ng/mL | Human EDTA K2 Plasma |
| Capecitabine; 5-DFCR | Oncology | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Capecitabine; 5-FU | Oncology | LC/MS/MS | 10-5000ng/mL | Human EDTA K2 Plasma |
| Captopril (free) | Cardiovascular | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Captopril (total) | Cardiovascular | LC/MS/MS | 2-750 ng/mL | Human EDTA Plasma |
| Carbamazepine | Central Nervous System Agents | LC/MS/MS | 100-5000 ng/mL | Human Plasma |
| Carbamazepine; 10,11-Epoxide Carbamazepine | Central Nervous System Agents | LC/MS | 50-5000 ng/mL ; 10-250 ng/mL | Human EDTA Plasma |
| Carbamazepine; 10,11-Epoxide Carbamazepine | Central Nervous System Agents | LC/MS/MS | 50-5000 ng/mL; 10-250 ng/mL | Human K3 EDTA Plasma |
| Carboplatin | TBD | ICP/MS | 1-100 µg/mL | Human EDTA Plasma |
| Carisoprodol; Meprobamate | Central Nervous System Agents | LC/MS/MS | TBD | Human Plasma |
| Carisoprodol; Meprobamate | Central Nervous System Agents | LC/MS/MS | 10-8000 ng/ml; 10-8000 ng/ml | Human EDTA Plasma |
| Carvedilol; 4'-Hydroxyphenylcarvedilol | Cardiovascular | LC/MS/MS | 0.25-80 ng/mL ; 100-7500 ng/mL | Human EDTA Plasma |
| Cefaclor | Infectious Disease | LC/MS/MS | 50-25000 ng/mL | Human EDTA Plasma |
| Cefadroxil | Infectious Disease | LC/MS/MS | 200-40000 ng/mL | Human EDTA Plasma |
| Cefatrizine | Infectious Disease | HPLC/FLR | 100-1000 ng/mL | Human EDTA K3 Plasma |
| Cefdinir | Infectious Disease | LC/MS/MS | 25-5000 ng/mL | Human EDTA K3 Plasma |
| Cefixime | Infectious Disease | LC/MS/MS | 20-10000 ng/mL | Human EDTA Plasma |
| Cefpodoxime | Infectious Disease | LC/MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Cefprozil (Z)-Isomer and Cefprozil (E)-Isomer | Infectious Disease | LC/MS/MS | 100-10000 ng/mL (Z) and 11 - 1110 ng/mL (E) | Human EDTA Plasma |
| Cefuroxime | Infectious Disease | HPLC/UV | 50-25000 ng/mL | Human EDTA Plasma |
| Celecoxib | Pain | LC/MS | 10-2000 ng/mL | Human Lithium Heparinized Plasma |
| Celecoxib | Pain | HPLC/UV | 10-2000 ng/mL | Human EDTA Plasma |
| Cephalexin | Infectious Disease | LC/MS/MS | 50-25000 ng/mL | Human EDTA Plasma |
| Cetirizine | Respiratory | HPLC/UV | 10-400 ng/mL | Human Plasma |
| Cetirizine | Respiratory | LC/MS | 2-200 ng/mL | Human EDTA K3 Plasma |
| Chlormadinone acetate; 3-hydroxy chlormadinone acetate | Endocrinology | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Chlorpheniramine | Respiratory | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Ciclopirox | Infectious Disease | LC/MS/MS | 20-10000 ng/mL | Mouse EDTA Plasma |
| Ciclopirox | Infectious Disease | LC/MS/MS | 5-5000 pg/mL | Human EDTA Plasma |
| Ciclopirox | Infectious Disease | LC/MS/MS | 1-500 ng/mL | Human urine |
| Ciclopirox | Infectious Disease | LC/MS/MS | 1-100 ng/mL | Rat Plasma |
| Ciclopirox | Infectious Disease | LC/MS/MS | 1-100 ng/mL | Human Urine |
| Ciclopirox-glucuronide | Infectious Disease | LC/MS/MS | 10-5000 ng/mL | Human urine |
| Ciclopirox-glucuronide | Infectious Disease | LC/MS/MS | 2.5-250 ng/mL | Human EDTA K3 Plasma |
| Ciclopirox-glucuronide | Infectious Disease | LC/MS/MS | 1-500 ng/mL | Rabbit EDTA K2 Plasma |
| Ciclopirox-glucuronide | Infectious Disease | LC/MS/MS | 1-500 ng/mL | Rat EDTA K2 Plasma |
| Cilostazol | Cardiovascular | LC/MS/MS | 5-1500 ng/mL | Human EDTA K3 Plasma |
| Cilostazol | Cardiovascular | LC/MS/MS | 5-1500 ng/mL | Human EDTA Plasma |
| Cilostazol;OPC-13213;OPC-13015 | Cardiovascular | LC/MS/MS | 5-1500 ng/mL; 1-100ng/mL ;2-200 ng/mL | Human EDTA Plasma |
| Cinacalcet | Rheumatology | LC/MS/MS | 100-50000 pg/mL | Human Plasma |
| Ciprofibrate | Cardiovascular | LC/MS | 0.25-50 µg/mL | Human Sodium Heparinized Plasma |
| Ciprofibrate | Cardiovascular | LC/MS | 0.25-50 µg/mL | Human EDTA Plasma |
| Ciprofloxacin | Infectious Disease | HPLC/FLR | 20-5000 ng/mL | Human EDTA Plasma |
| Ciprofloxacin | Infectious Disease | HPLC/FL | 20-5000 ng/mL | Human Plasma |
| Cisapride; Norcisapride | Gastrointestinal | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Citalopram | Central Nervous System Agents | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Citalopram | Central Nervous System Agents | LC/MS/MS | 0.2-75 ng/mL | Human EDTA Plasma |
| Citalopram | Central Nervous System Agents | LC/MS/MS | 0.2-75 ng/mL | Human K3 EDTA Plasma |
| Cizolirtine; Desmethylcizolirtine | Pain | LC/MS/MS | 1-2000 ng/ml; 1-2000 ng/ml | Human Na Hep plasma |
| Clarithromycin | Infectious Disease | HPLC/MS/MS | 0.1-10 µg/mL | Human Plasma |
| Clarithromycin | Infectious Disease | LC/MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Clavulanic Acid | Infectious Disease | LC/MS/MS | 40-4000 ng/mL | Human EDTA Plasma |
| Clindamycin | Infectious Disease | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Clomiphene cis (Z) and trans (E) Isomers | Endocrinology | LC/MS/MS | 100-20000 pg/mL; 50-10000 pg/mL | Human EDTA Plasma |
| Clonazepam | Central Nervous System Agents | LC/MS/MS | 100-50000 ng/mL | Human EDTA Plasma |
| Clonidine | Cardiovascular | LC/MS/MS | 10-400 pg/mL | Human EDTA Plasma |
| Clopidogrel | Cardiovascular | LC/MS/MS | 5-2500 pg/mL | Human EDTA Plasma |
| Clopidogrel | Cardiovascular | LC/MS/MS | 20-10000 pg/ml | Rat EDTA K3 plasma |
| Clopidogrel | Cardiovascular | LC/MS/MS | 5-2500 pg/mL | Human Sodium Heparin Plasma |
| Clopidogrel Carboxylic Acid | Cardiovascular | LC/MS/MS | 15-7500 ng/mL | Rat EDTA Plasma |
| Clopidogrel Carboxylic Acid | Cardiovascular | LC/MS/MS | 4-4000 ng/mL | Human EDTA Plasma |
| Clotrimazole | Infectious Disease | LC/MS/MS | 1-100 ng/mL | Human Plasma |
| Clotrimazole | Infectious Disease | LC/MS/MS | 0.1-20 ug/mL | Human Saliva |
| Clozapine | Central Nervous System Agents | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Clozapine; N-Desmethylclozapine | Central Nervous System Agents | LC/MS/MS | 2-1000 ng/mL; 1-500 ng/mL | Human EDTA Plasma |
| Cocaine;Benzoylecgonine | Miscellaneous | LC/MS/MS | 5-500 ng/mL;10-1000 ng/mL | Human EDTA Plasma |
| Codeine | Pain | LC/MS/MS | 0.5-100 ng/mL | Human EDTA K3 Plasma |
| Codeine, Norcodeine and Codeine-6-Glucuronide | Pain | LC/MS/MS | 0.5-100 ng/mL, 2-400 ng/mL, 2-400 ng/mL | Human EDTA K3 Plasma |
| Colchicine | Rheumatology | LC/MS/MS | 40-10000 pg/mL | Human EDTA K3 Plasma |
| Cortisol | Endocrinology | RIA | 5-200 ng/mL | Human Serum |
| Cortisol | Endocrinology | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Cortisol | Endocrinology | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Cyclosporin A | Immunology | LC/MS/MS | 2-1000 ng/mL | Human EDTA Whole Blood |
| Cyproterone Acetate | Endocrinology | LC/MS/MS | 100-40000 pg/mL | Human EDTA Plasma |
| Cytarabine and ARA-U | Oncology | LC/MS/MS | 1-100 µg/mL and 100-10000 ng/mL | Rat EDTA Plasma |